Akeso, Inc. (HK:9926) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Akeso, Inc. has expanded its license agreement with Summit Therapeutics Inc., now including exclusive development and commercialization rights for its bi-specific antibody, ivonescimab, in additional regions such as Central and South America, the Middle East, and Africa. The amendment promises Akeso up to $70 million in upfront and milestone payments, plus sales royalties. Ivonescimab, which has been approved in China for certain lung cancer treatments, is undergoing multiple clinical trials for various indications.
For further insights into HK:9926 stock, check out TipRanks’ Stock Analysis page.